ETON logo

Eton Pharmaceuticals (ETON) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

13 November 2018

Indexes:

Not included

Description:

Eton Pharmaceuticals is a healthcare company that focuses on developing and commercializing specialty pharmaceuticals. They create unique medicines for patients with specific needs, often improving existing treatments. Eton aims to enhance patient care by providing innovative solutions in the pharmaceutical market.

Events Calendar

Earnings

Next earnings date:

Mar 14, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 14, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

26 Nov '24 HC Wainwright & Co.
Buy
13 Nov '24 HC Wainwright & Co.
Buy
28 Oct '24 Craig-Hallum
Buy
04 Oct '24 HC Wainwright & Co.
Buy
04 Oct '24 Craig-Hallum
Buy
06 May '24 Craig-Hallum
Buy
11 Dec '23 HC Wainwright & Co.
Buy
11 Aug '23 HC Wainwright & Co.
Buy
03 July '23 HC Wainwright & Co.
Buy
21 Mar '23 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
ETON
globenewswire.com03 January 2025

DEER PARK, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired Galzin® (zinc acetate).

What Makes Eton Pharmaceuticals (ETON) a Good Fit for 'Trend Investing'
What Makes Eton Pharmaceuticals (ETON) a Good Fit for 'Trend Investing'
What Makes Eton Pharmaceuticals (ETON) a Good Fit for 'Trend Investing'
ETON
zacks.com18 November 2024

Eton Pharmaceuticals (ETON) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript
ETON
seekingalpha.com12 November 2024

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants David Krempa – Chief Business Officer Sean Brynjelsen – Chief Executive Officer James Gruber – Chief Financial Officer Conference Call Participants Chase Knickerbocker – Craig-Hallum Operator Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode.

Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Transcript
ETON
seekingalpha.com11 August 2024

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to the Eaton Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please be advised, this call is being recorded at the company's request.

Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
ETON
globenewswire.com08 August 2024

DEER PARK, Ill., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2024.

Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
ETON
globenewswire.com30 July 2024

DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
ETON
globenewswire.com15 July 2024

- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the Company's New Drug Application (NDA) for ET-400, a proprietary patented formulation of hydrocortisone oral solution, has been accepted by the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025.

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
ETON
GlobeNewsWire01 May 2024

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a pharmaceutical company specializing in rare disease treatments, will have its CEO Sean Brynjelsen and CFO James Gruber present at the Citizens JMP Life Sciences Conference in New York.

Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript
Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript
ETON
Seeking Alpha14 March 2024

Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
ETON
Zacks Investment Research14 March 2024

Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.04 per share a year ago.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the primary business of Eton Pharmaceuticals?
  • What is the ticker symbol for Eton Pharmaceuticals?
  • Does Eton Pharmaceuticals pay dividends?
  • What sector is Eton Pharmaceuticals in?
  • What industry is Eton Pharmaceuticals in?
  • What country is Eton Pharmaceuticals based in?
  • When did Eton Pharmaceuticals go public?
  • Is Eton Pharmaceuticals in the S&P 500?
  • Is Eton Pharmaceuticals in the NASDAQ 100?
  • Is Eton Pharmaceuticals in the Dow Jones?
  • When was Eton Pharmaceuticals's last earnings report?
  • When does Eton Pharmaceuticals report earnings?
  • Should I buy Eton Pharmaceuticals stock now?

What is the primary business of Eton Pharmaceuticals?

Eton Pharmaceuticals is a healthcare company that focuses on developing and commercializing specialty pharmaceuticals. They create unique medicines for patients with specific needs, often improving existing treatments. Eton aims to enhance patient care by providing innovative solutions in the pharmaceutical market.

What is the ticker symbol for Eton Pharmaceuticals?

The ticker symbol for Eton Pharmaceuticals is NASDAQ:ETON

Does Eton Pharmaceuticals pay dividends?

No, Eton Pharmaceuticals does not pay dividends

What sector is Eton Pharmaceuticals in?

Eton Pharmaceuticals is in the Healthcare sector

What industry is Eton Pharmaceuticals in?

Eton Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry

What country is Eton Pharmaceuticals based in?

Eton Pharmaceuticals is headquartered in United States

When did Eton Pharmaceuticals go public?

Eton Pharmaceuticals's initial public offering (IPO) was on 13 November 2018

Is Eton Pharmaceuticals in the S&P 500?

No, Eton Pharmaceuticals is not included in the S&P 500 index

Is Eton Pharmaceuticals in the NASDAQ 100?

No, Eton Pharmaceuticals is not included in the NASDAQ 100 index

Is Eton Pharmaceuticals in the Dow Jones?

No, Eton Pharmaceuticals is not included in the Dow Jones index

When was Eton Pharmaceuticals's last earnings report?

Eton Pharmaceuticals's most recent earnings report was on 12 November 2024

When does Eton Pharmaceuticals report earnings?

The next expected earnings date for Eton Pharmaceuticals is 14 March 2025

Should I buy Eton Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions